Research programme: xeroderma pigmentosum group A protein inhibitors - NERx Biosciences
Alternative Names: NERx X80 class of compounds - NERx Biosciences; NERx-X80Latest Information Update: 28 Sep 2025
At a glance
- Originator NERx Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA repair inhibitors; DNA-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Cancer in USA
- 20 Sep 2023 Xeroderma pigmentosum group A protein inhibitors are still in preclinical development for Cancer in USA (NERx Biosciences pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in USA